Company: GNMSF
Filing Date: 2025-09-29
Form Type: SC TO-C
Source: 0000947871-25-000868
Chunk: 2

Company: GENMAB A/S
Filing Date: 2025-09-29
Form: SC TO-C
Chunk 2
---
ITATION/RECOMMENDATION STATEMENT AND THE PROXY STATEMENT WILL CONTAIN IMPORTANT INFORMATION. SHAREHOLDERS OF THE COMPANY ARE URGED TO READ THESE DOCUMENTS CAREFULLY WHEN THEY BECOME AVAILABLE (AS EACH MAY BE AMENDED OR SUPPLEMENTED FROM TIME TO TIME) BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION THAT HOLDERS OF COMMON SHARES SHOULD CONSIDER BEFORE MAKING ANY DECISION WITH RESPECT TO THE TENDER OFFER OR MAKING ANY VOTING DECISION. The tender offer for Common Shares will be made only
pursuant to the Offer to Purchase, the Letter of Transmittal and related documents filed as a part of the Tender Offer Statement.
The Tender Offer Statement (including the Offer to Purchase, the related Letter of Transmittal and certain other tender offer
documents), as well as the Solicitation/Recommendation Statement, will be made available to all holders of Common Shares at no
expense to them. The Tender Offer Statement and the Solicitation/Recommendation Statement will be made available for free at the
SEC’s website at www.sec.gov. Copies of the documents filed by Genmab or Purchaser with the SEC will also be available free of
charge on Parent’s website at https://www.genmab.com/investor-relations or by contacting Genmab’s investor relations
department at ir@genmab.com. Copies of the documents filed by the Company with the SEC will also be available free of charge on the
Company’s website at https://ir.merus.nl/ or by contacting the Company’s investor relations department at
s.spear@merus.nl. In addition, shareholders of the Company may obtain free copies of the tender offer materials by contacting the
information agent for the tender offer that will be named in the Tender Offer Statement.

Forward-looking Statements

This Company Announcement
contains forward looking statements. The words “believe,” “expect,” “anticipate,”
“intend” and “plan” and similar expressions identify forward looking statements. Statements in this Company
Announcement that are forward looking may include, but are not limited to, statements regarding the benefits of the proposed
transaction; the development plan, regulatory approval, data release timing, commercial launch timing and revenue potential of
petosemtamab; the expected timing of the closing of the proposed transaction; and Genmab’s expectations regarding financing
the proposed transaction, de-levering and timing of new drug launches. Actual results or performance may differ